Janux Therapeutics, Inc. (JANX) financial statements (2022 and earlier)

Company profile

Business Address 11099 TORREY PINES PARK ROAD
SAN DIEGO, CA 92037
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments374,965
Cash and cash equivalents35,582
Short-term investments339,383
Other undisclosed current assets2,054
Total current assets:377,019
Noncurrent Assets
Operating lease, right-of-use asset185
Property, plant and equipment1,412
Restricted cash and investments816
Other noncurrent assets392
Total noncurrent assets:2,805
TOTAL ASSETS:379,824
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,408
Accounts payable2,458
Accrued liabilities3,779
Employee-related liabilities1,171
Deferred revenue5,163
Other undisclosed current liabilities226
Total current liabilities:12,797
Noncurrent Liabilities
Liabilities, other than long-term debt700
Deferred revenue700
Total noncurrent liabilities:700
Total liabilities:13,497
Stockholders' equity
Stockholders' equity attributable to parent366,327
Common stock41
Additional paid in capital413,967
Accumulated other comprehensive loss(270)
Accumulated deficit(47,411)
Total stockholders' equity:366,327
TOTAL LIABILITIES AND EQUITY:379,824

Income statement (P&L) ($ in thousands)

12/31/2021
Revenues3,637
Gross profit:3,637
Operating expenses(36,566)
Operating loss:(32,929)
Nonoperating income257
Net loss available to common stockholders, diluted:(32,672)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(32,672)
Other undisclosed comprehensive loss(270)
Comprehensive loss, net of tax, attributable to parent:(32,942)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: